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Abstract
Pax6 plays an important role in embryonic cell (ES) differentiation during embryonic development. Expression of Pax6
undergoes from a low level to high levels following ES cell differentiation to neural stem cells, and then fades away in most
of the differentiated cell types. There is a limited knowledge concerning how Pax6 is regulated in ES cell differentiation. We
report that Pax6 expression in mouse ES cells was controlled by CCCTC binding factor (CTCF) through a promoter repression
mechanism. Pax6 expression was significantly enhanced while CTCF activity was kept in the constant during ES cell
differentiation to radial glial cells. Instead, the interaction of CTCF with Pax6 gene was regulated by decreased CTCF
occupancy in its binding motifs upstream from Pax6 P0 promoter following the course of ES cell differentiation. Reduced
occupancy of CTCF in the binding motif region upstream from the P0 promoter was due to increased DNA methylations in
the CpG sites identified in the region. Furthermore, changes in DNA methylation levels in vitro and in vivo effectively altered
methylation status of these identified CpG sites, which affected ability of CTCF to interact with the P0 promoter, resulting in
increases in Pax6 expression. We conclude that there is an epigenetic mechanism involving regulations of Pax6 gene during
ES cell differentiation to neural stem cells, which is through increases or decreases in methylation levels of Pax6 gene to
effectively alter the ability of CTCF in control of Pax6 expression, respectively.
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Introduction
Regeneration of neural progenitor cells in vitro from embryonic
stem (ES) cells is one of the promising methods to meet
neurogenesis requirements in neurodegenerative therapy [1,2,3].
However, a major problem needs to be solved when inducing ES
cells to generate neuronal stem cells is the heterogeneity. Improved
methods have been developed to generate a certain type of
neuronal stem cells, or called radial glial cells [4,5,6]. Radial glial
cells have dual functions to produce neurons and to guide
migration of the newly formed neurons [7,8]. Recent studies
demonstrate that treating ES cells with retinoid acid (RA) induces
ES cell differentiation to become a pure population of the
precursor cells that not only express a set of radial glial cell
markers, but also have an enhanced expression of Pax6. However,
Pax6 rapidly fades away when radial glial cells start terminal
differentiation becoming neurons [4,5]. Due to dynamic changes
in Pax6 expression during committed neuronal differentiation of
ES cells, Pax6 may be a key factor that controls the specification of
radial glial cell differentiation in vitro.
Homeobox transcription factor Pax6 is highly conserved among
vertebrate and invertebrate species and is crucial for the development
of the eye, pancreatic islet cells and the central nervous system (CNS).
Pax6 mutations cause the small eye (Sey) defect in mice and ocular
aniridia in humans [9]. During normal CNS development, Pax6
regulates the balance between self-renewal and neurogenesis in
neuronal precursors cells in a dose-dependant fashion, which reflects
a need for a critical level of Pax6 at the certain stage of neuronal
differentiation [10]. However, there is a limited knowledge about
regulation of Pax6 in CNS development. Remaining questions are
why there is a significant up-regulated Pax6 expression in neural
differentiation toward radial glial cells, and what causes down-
regulation of Pax6 during the terminal differentiation later. It is
important to find answers for these questions in order to understand
mechanismsinvolvingregulationofPax6 and to ultimately controlthe
process of neural differentiation.
In most species, Pax6 transcription is regulated via P0 and P1
promoters [11,12,13]. There is a highly conserved transcription
control element, termed ectoderm enhancer (EE). EE is located
approximately 23.5 kbp upstream from the P0 promoter, which is
important for promoting specific expression of Pax6, and to
regulate retina- and neuro-specific gene expression [13]. Another
regulatory element is located in intron 4 of the gene to direct
activities of P0 and P1 promoters in the ciliary body, iris and
amacrine cells [13]. The most recent report indicates that Pax6
expression is regulated by CTCF, a zinc finger protein (ZFP)
[14,15,16]. CTCF is a multivalent eukaryotic transcription factor
that interacts with DNA sequences in the region of Pax6 P0
promoter to block the interaction between the EE element and
Pax6 P0 promoter [15,16,17].
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DNA imprinting, X chromosome inactivation and transcriptional
controls of gene expression [18,19]. CTCF is initially character-
ized as a negative and positive regulator because of its capability to
bind to DNA motifs in the promoter of various genes, including c-
myc, p19ARF, p16INK4a, PIM-1, PLK, BRCA1, TERT and Pax6
[16,20,21,22,23]. Later, there are new discoveries that demon-
strate that CTCF functions as a unique insulator protein to
regulate gene expression in both chicken globin and h19/Igf2 loci
[24,25]. It also regulates communications between adjacent
regulatory DNA elements in a position-dependent manner, or
serves as a barrier to buffer transgenes from position effects caused
by spread of the repressive heterochromatin from adjacent
sequences [18,23]. The binding of CTCF to insulator sequences
or DNA boundary elements is often sensitive to modification of
DNA methylation (CH3) that usually inhibits CTCF binding and
eliminates CTCF-dependent actions [21,26].
Previous study reveals that there is a repressor element located
in promoter of Pax6 gene containing five CCCTC motifs within a
sequence of 80-bp nuclear acids. All of the five CCCTC motifs in
this region are functional for the CTCF action [16]. The
repressive effect of CTCF on Pax6 expression is required for
growth factor-induced proliferation [27]. In addition, ultraviolet
(UV) irradiation inhibits CTCF expression that minimizes CTCF
binding to the repressor element of Pax6 [17,28,29]. In fact, over-
expression of CTCF in transgenic mice suppresses Pax6 gene
expression resulting in retardation of embryonic ocular develop-
ment including the cornea, lens and retina [15,16]. In the present
study, we generated neural stem cells from ES cells and obtained
radial glial cells with enhanced Pax6 expression. This in vitro
differentiation procedure was applied as a working model to
investigate the effect of CTCF on Pax6 expression dynamically,
and to further understand the regulatory mechanism underlying
Pax6 expression in early stages of ES and radial glial cells. Our
data revealed an epigenetic mechanism indicating that increases
and decreases in the methylation levels of Pax6 gene effectively
alter the ability of CTCF to control Pax6 expression.
Results
Induction of radial glial cells from embryonic stem cells
In the present study, a previous established protocol was used to
induce ES cell differentiation toward radial glial cells [4,5].
Cultured mouse ES cells were transferred to petri-dishes and
treated with RA. Photos were taken by a Nikon invert microscope
to document morphological changes of RA-induced ES cells in
different stages of differentiation (Fig. 1A). Results of RA-induced
ES differentiation followed a pattern that was consistent with
Figure 1. Induction of radial glial cells from embryonic stem cells. (A) Morphological changes of neural differentiation from ES cells. (B)
Altered mRNA expression of ES cell markers (Oct4) and radial gial cells markers (nestin, BLBP and Pax6). (C) Staining for radial gial cells markers. ES
cells growing on gelatin-coated plates were dissociated and transferred to nonadherent bacterial dishes to form embryonic body. After 4-day of
embryonic body formation, 5 mM retinoid acid was added to the culture media and cells were allowed to grow for another 4 days. Embryonic bodies
were dissociated after a total of 8-day induction and plated to poly-D-lysine/laminin-coated dishes in N2 medium. N2 medium is changed after 2 h.
Cell samples were collected before and after the 4 days and days induction as shown as ES (0 d), EB (4 d) and EB (8 d) respectively. Photos of RG cells
were taken 6 h after passage. Total RNAs were extracted at indicated time points and altered expressions of cell lineage-specific markers were
monitored by RT-PCR. Cells were immunostained with antibodies specific to Nestin (green) and Pax6 (red). Cell nuclei were stained by DAPI (Blue).
Results were plotted as a percentage of positively stained cells with Nestin and Pax6 antibodies vs numbers of DAPI-positive nuclei.
doi:10.1371/journal.pone.0020954.g001
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induced cells were successfully differentiated to spindle-shaped
radial glial cells. Results from RT-PCR revealed that mRNAs of
nestin (neural precursor marker) and BLBP (radial glial cell
marker) were highly expressed, while expression of Oct4 mRNA
(an ES cell marker) was suppressed in 8 days in RA-induced cells
(Fig. 1B). More importantly, expression of Pax6 mRNA was
dramatically increased in the 8
th day in RA-induced cells. Nestin-
and Pax6-positive cells were identified by immunostaining
experiments in RA-induced cells, demonstrating that there was a
significantly high conversion of ES cells to the radial glial cells
(Fig. 1C). These results indicate that Pax6 is regulated during ES
cell differentiation toward radial glial cells.
Regulation of Pax6 expression by CTCF in ES cells
Our previous studies have demonstrated that CTCF is a negative
regulator of Pax6 gene in the cornea and retina. To study whether
CTCF also involves regulation of Pax6 in mouse ES cells, CTCF-
specific siRNA was transfected to ES cells to knock down CTCF
mRNA. We found that expression of CTCF at the protein level was
decreased about 75% in ES cells transfected with CTCF-specific
siRNA at 72 h (Fig. 2A&2B). At the same time (72 h), expression of
Pax6 protein was significantly increased following knockdown of
CTCF (Fig. 2A&2C). For control experiments, ES cells were
transfected with non-silencing control siRNA following the same
procedure and time course as the experimental group. The results
demonstrate that altered levels of CTCF by knockdown of CTCF
mRNA in ES cells result in up-regulation of Pax6 expression.
Effect of RA-induced ES cell differentiation on CTCF activity
Based on the observation that Pax6 expression was regulated by
CTCF in ES cells, we investigated whether CTCF activity was also
changed to correlate to the altered Pax6 expression during the time
course of ES cell differentiation to radial glial cells. The effect of
RA-induced ES differentiation on CTCF activity was investigated
by focusing on two respects that include the CTCF expression
level and its DNA binding capacity. First, both mRNA and protein
expressions of CTCF were monitored following the time course of
ES cell differentiation (Fig. 3A&3B). We found that Pax6
expression markedly increased on the 8
th day of EB formation,
and that there were no changes in CTCF expression at either the
protein or mRNA level. Second, association of CTCF with the
binding motifs in the promoter of Pax6 gene was examined. It has
been shown that CTCF binds as a repressor to the region of
21.2 kb upstream from Pax6 P0 promoter to suppress Pax6
transcription [16]. A set of primers was designed accordingly for
chromatin immunoprecipitation (ChIP)-based PCR experiments
to generate a 260 bp DNA fragment based on consensus DNA
sequences upstream from the Pax6 P0 promoter within the region
of CTCF binding motifs (Fig. 3C). Results of ChIP-based PCR
using specific antibodies against CTCF revealed that there were
remarkable decreases in CTCF binding on DNA motifs in Pax6
promoter region on the 8
th day of EB formation. For controls,
non-immunoprecipitated chromatins were used as DNA templates
in PCR experiments (labeled as input) (Fig. 3D). Taken together,
CTCF expression was not affected by ES cell differentiation,
instead its binding ability to DNA motifs in Pax6 promoter was
Figure 2. Effect of altered CTCF activity on Pax6 expression in ES cells. (A) Effect of knocking down CTCF mRNA on Pax6 expression.
Statistical analysis of suppressed CTCF expression (B) and increased Pax6 expression (C). Data was shown as mean 6S.E. Symbol ‘‘*’’ indicates
significant differences (p,0.05, n=4).
doi:10.1371/journal.pone.0020954.g002
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differentiation to radial glial cells are very likely resulted from
disengaging CTCF from its binding motifs and releasing Pax6
promoter from the repressor effect of CTCF.
Methylation-modification within CTCF binding region
It has shown that the interaction of CTCF with DNA sequence
can be inhibited if the binding motif is methylated [18]. Next
question is whether DNA methylation affects associations of
CTCF with Pax6 DNA since CTCF binding capacity to Pax6
DNA decreased during radial glial cell differentiation. First,
several potential 5-methylcytosines were located in the 80 bp
region of CTCF binding motifs through DNA sequence analyzing
(Fig. 4A). Genomic DNAs from ES cells were isolated and treated
with sodium bisulfite that converts unmethylated cytosine to uracil
while leaving 5-methylcytosine unchanged. DNA fragments
containing CTCF binding sites were obtained by PCR with
primers specific to bisulfite-converted DNA and sequenced for
conformation. Normal genomic DNAs without sodium bisulfite
treatment were also isolated for control experiments. In the PCR
products, only 5-methylcytosines remained as cytosines (C) while
un-methylcytosines were converted to thymines (T). Sequencing
results revealed that within the tested DNA region, there were
mixed C/T pairs occurring in 3 positions (sites 1–3 shown in
Fig. 4A), indicating an uneven methylation of cytosine residues. All
of other cytosine residues in CG-rich islands were completely
converted to T (data not shown). Sites 1–3 were subjects to further
quantitative analysis by performing Ms-SNuPE assays. These sites
were differentially mehylated showing that methylations occurred
about 15% in site 1, 55% in sties 2 and 3 (Fig. 4B&4C). To further
verify methylation data, methylation responses of these sites were
examined by altering cellular DNA methylation levels. ES cells
were treated with 1 mM of 5-azadCyd to suppress methyltransfer-
ase resulting in decrease in DNA methylation. In contrast, ES cells
were transfected with full-length cDNA encoding methyltranferase
Dnmt3a to increase DNA methylation. Results showed: 1) site 1
was about 15% methylated in control cells compared to 12% and
18% methylated in 5-azadCyd treated and Dnmt3a-transfected
cells, respectively; and 2) both sites 2 and 3 were approximate 55%
methylated in control cells compared to 32% and 80% methylated
in 5-azadCyd-treated and Dnmt3a-transfected cells, respectively
(Fig. 4C). These results suggest that there are at least three cytosine
residues that respond to alterations of cellular DNA methylation
levels located in the region of CTCF binding motifs.
Changed DNA methylation in CTCF binding region
during differentiation
DNA methylation statuses of 3 cytosine residues within sites 1–3
were monitored during ES cell differentiation to radial glial cells.
DNA samples were taken from cells in three stages: un-
differentiated ES cells before the induction, on EB 4
th day and
EB 8
th day after the induction. Ms-SNuPE assays were preformed
to quantitatively evaluate methylation levels of sites 1–3. Levels of
5-methylcytosines in sites 1–3 were measured by using
32P-dCTP
Figure 3. Correlation of CTCF and Pax6 in ES cell differentiation to radial glial cells. (A) Expressions of CTCF and Pax6 mRNAs during ES cell
differentiation to radial glial cells. Total RNA samples were harvested from undifferentiated ES cells (0 d) and embryonic body (EB) cells after 4 day or
8 day induction. RT-PCR assays were performed to measure the expression of CTCF, Pax6 and GAPDH. (B) Expressions of CTCF and Pax6 proteins
during ES cell differentiation to radial glial cells. Western assays were performed to detect expression levels of CTCF, Pax6 and b-actin. (C) Illustration
of ChIP-based PCR designs. (D) Detection of specific protein-nucleotide interaction between CTCF and Pax6 gene during ES cell differentiation and EB
formation. Chromatin samples were immuno-pulled down by CTCF-specific antibody. ChIP-based PCR was performed to amplify CTCF binding DNA
fragment in Pax6 P0 promoter region. All ChIP and pCR experiments were repeated for at least three times.
doi:10.1371/journal.pone.0020954.g003
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upstream from Pax6 promoter. (B) Quantitative determination of methylation status at cytosines in CTCF binding sties after inductions of
demethylation and methylation. Genomic DNA is treated with sodium bisulfite followed by PCR of the target sequence to generate the template for
Ms-SNuPE assays. Methylation statuses were evaluated by the radio of radial incorporation of
[32]P-dCTP (representing methylated cytosine) and
[32]P-
dTTP (representing unmethylated cytosines). DNA methylations were detected by using bisulfite sodium modifications and PCR. Demethylation and
methylation were induced by 5-azadCyd (1 mM) and by over-expression of Dnmt3a, respectively. (C) Statistical analysis of methylation percentages in
site1–3. Data was shown as mean 6S.E. and represented results from three independent Ms-SNuPE assays. Symbol ‘‘*’’ indicates significant
differences comparing with cells without treatment. (p,0.05, n=3).
doi:10.1371/journal.pone.0020954.g004
Figure 5. Methylation status of CTCF binding region in Pax6 promoter during ES cell differentiation to radial glial cells. (A) Detecting
changes of DNA methylation in CTCF binding sites during ES cell differentiation and EB formation. (B) Statistical analysis of DNA methylation changes
in CTCF binding motifs during ES cell differentiation and EB formation. The genomic DNA harvested from ES cells and EB cells at different stages was
treated with sodium bisulfite followed by PCR of the target sequence to generate the template for Ms-SNuPE assays. Methylated cytosines at site 1–3
were revealed by
[32]P-dCTP incorporation. Symbol ‘‘*’’ indicates the statistical significance determined by Student’s t test at p,0.05 (n=3).
doi:10.1371/journal.pone.0020954.g005
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levels in those measured sites between ES cells and EB at 4
th day
(Fig. 5A). However, methylation levels were significantly increased
in all of the three sites on the 8
th day of EB formation (Fig. 5A&5B).
The results demonstrate an increased DNA methylation levels
within CTCF binding motifs located in Pax6 promoter region.
Increases in DNA methylation in this region following the time
course of ES cell differentiation may result in inhibition of CTCF
binding to the Pax6 promoter.
Effect of DNA methylation on CTCF protein-nucleotide
interaction
To study the specific effect of DNA methylation on CTCF binding
capability to the Pax6 promoter, EMSA/super-shift assays and ChIP-
based PCR were performed to evaluate the DNA binding capability
of CTCF. First, EMSA and super-shift assays were performed with
synthesized and
32P-labelled DNA probes. These probes contained
four CTCF binding sites in the 80 bp fragment upstream from the
promoter. The probes were un-methylated or methylated in all of the
three-cytosine sites. DNA-protein complexes were formed in nuclear
extracts when those un-methylated probes were used and the binding
between DNA and protein was competed by un-labeled probes, but
not by nonspecific control probes (Fig. 6A). Furthermore, there was a
super-shift band found in cell nuclear extracts incubated with CTCF-
specific antibodies, however, there were no super-shift bands in the
control sample treated with c-Jun antibodies. In contrast, there were
no specific bands found in lanes that were treated with methylated
probes, indicating that there was no DNA-protein complex formed
(Figure 6A). The results demonstrate that DNA methylation negatively
affects CTCF-specific binding activity in its motifs upstream from the
Pax6promoter. To further verify the methylation-sensitive interaction
between CTCF and the Pax6 promoter, ChIP-based PCR were
performed to detect the binding capacity of CTCF with the Pax6
promoter in ES cells in the absence and presence of 5-azadCyd.
Consistently, results of ChIP assays demonstrated remarkably
enhanced bands in demethylation-induced ES cells when the CTCF
specific antibody was used to pull down chromatins (Fig. 6B). Results
from both EMSA and ChIP-based PCR experiments indicate that
there are indeed methylation-sensitive interactions between CTCF
and Pax6 gene in ES cells.
Effect of DNA methylation on Pax6 expression
Effects of altered DNA methylation on Pax6 expression in 5-
azadCyd-treated and Dmnt3a-transfected cells were monitored by
Western analysis. Treatment of 5-azadCyd induced DNA de-
methylation down-regulated Pax6 expression (Fig. 7A). In contrast,
over-expression of Dnmt3a by transfecting cells with full-length
cDNA encoding Dnmt3 up-regulated Pax6 expression following a
time course (Fig. 7B). Statistical analysis showed that Pax6 expression
was significantly increased after over-expression of Dnmt3. The result
is consistent with the observation that there was an increased DNA
methylation in the CTCF binding motifs in the Pax6 promoter
region, and that there was an increased Pax6 expression on the 8
th
day of EB formation during ES cell differentiation to radial glial cells.
Taken together, our data support the notion that there are increased
DNA methylation in the region of CTCF binding motifs upstream
from the Pax6 promoter can exclude CTCF binding in the region
during the period of ES cell differentiation to radial glial cells, which
abolishes the repressor effect of CTCF on Pax6 promoter activity,
resulting in an enhanced Pax6 expression.
Discussion
Neural progenitor cells derived from ES cells can be a promising
candidate for the cell-replacement therapy for neurodegenerative
and retinal diseases [3]. To generate a homogenous resource of
neural progenitor cells, it is important to identify key factors that can
be used not only as an indicator of neural differentiation, but also as
an entry point to manipulate the conversion course. Pax6 appears to
Figure 6. Effect of DNA methylation or de-methylation on protein-nucleotide interaction of CTCF and Pax6 gene. (A) DNA and nuclear
protein interactions were detected by EMSA using demethylated and methylated CTCF-specific DNA probes. Anti-CTCF antibody was used to detect
DNA-protein complex super-shift. In addition, AP-1 DNA probe and c-Jun antibody were used in control experiments for DNA binding competition
and super-shift experiments, respectively. Radioactive signals were visualized by exposure of the EMSA gel to X-ray film. (B) Significant increase in
specific protein-nucleotide binding of CTCF to Pax6 gene in demethylated ES cells. Chromatin samples in 1 mM 5-azadCyd-induced ES cells were
immuno-pulled down by CTCF-specific antibody. ChIP-based PCR was performed to amplify the CTCF-binding motif DNA fragment in Pax6 promoter
region. Data were obtained from three independent ChIP and PCR experiments. Symbol ‘‘*’’ indicates significant differences (p,0.05, n=3).
doi:10.1371/journal.pone.0020954.g006
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neural stem cells self-renewal and neurogenesis [10,30,31]. There
are three types of neural stem cells during CNS development,
including neuroepithelial cells, radial glial cells and basal progenitor
cells [7,30]. Pax6 is a key factor in the specification of radial glial cells
[5,32,33]. Loss function of Pax6 leads to the transition from
predominantly radial glial cell-based neurogenesis to basal progen-
itor cell-based neurogenesis [30]. More importantly, regulation of
CNS development by Pax6 is sensitive to Pax6 dosages that is
evidenced by the followings: 1) heterozygous human mutation of
Pax6 results in aniridia and forebrain abnormalities; 2) homozygous
human and mouse mutations of Pax6 lack eyes and have marked
microcephaly and absent olfactory bulbs; 3) increased expression of
Pax6 in transgenic mice results in microphthalmia and forebrain
abnormalities [10]. In addition, during the course of in vitro
conversion of ES cells to neural cells via an intermediate radial
glial cell stage, Pax6 expression exhibits extensive changes with the
peak expression level in RG cells [4,5]. In the present study, we have
monitored Pax6 expression patterns and the control of Pax6
expression by CTCF in an established model in vitro during
generating radial glial cells from ES cells. The mechanism involving
CTCF occupancy and DNA methylation in CTCF-specific binding
location in Pax6 promoter explains how up-regulation of Pax6 occurs
in a certain stage of EB formation. All these in vivo and in vitro
investigations are consistent with previous study results, indicating
that Pax6 expression must be under tight control during neural
differentiation.
Differentiation of ES cells is initiated by cell aggregation in non-
tissue culture plates, and then by adding retinoid acid on the 4
th
day of EB formation. Pax6 expression was tremendously enhanced
on the 8
th day of EB formation accompanied with suppressed Oct4
expression, and with enhanced expressions of BLBP and nestin
that are markers for radial glia and neuronal precursor cells (Fig. 1).
These results are reminiscent of previous reports and prompted us
to investigate what causes the dramatically increase in Pax6 activity
in radial glial cells [4,5]. We consistently observed a slight down-
regulated Pax6 expression both at its mRNA and protein levels on
the 4
th day of RA-induced differentiation. The association between
CTCF protein and Pax6 promoter may have not been affected yet
on the 4
th day of the induction, suggesting that other mechanisms
are involved in down-regulating Pax6 expression. One possibility is
that Pax6 expression may be regulated by altered microRNA levels
at this stage as it has been shown in neuron progenitor cells
microRNA-9 indirectly inhibits Pax6 expression [34].
Previous studies found that the epigenetic regulator CTCF
negatively controls transcription of the Pax6 gene in ocular tissues
[16]. Here, we demonstrate that CTCF also involved in regulation
of Pax6 in ES cells by showing that deficiency of CTCF by
knocking down CTCF mRNA significantly could enhance Pax6
expression (Fig. 2). Expression levels of CTCF mRNA and protein
were not changed in the entire period of monitoring ES cell
differentiation to radial glial cells. In stead, capability of CTCF
interacting with its binding motif located upstream from Pax6
promoter was remarkably reduced on the 8
th day of EB formation,
Figure 7. Effect of DNA methylation or de-methylation on Pax6 gene expression. (A) Effect of decreasing DNA methylation on Pax6 gene
expression in ES cells. ES cells were treated with 1 mM 5-azadCyd for 24 and 48 h and subjected to Western analysis to compare the Pax6 expression
w/wo 5-azadCyd-mediated de-methylation treatment. (B) Effect of increasing DNA methylation on Pax6 gene expression in ES cells. ES cells were
transfected with full-length cDNA encoding Dmnt3a for 24–72 h and protein levels of Pax6, CTCF, Dmnt3a and b-actin were determined by Western
analysis. (C) Data was shown as mean 6S.E. obtained from three independent experiments. Symbol ‘‘*’’ indicates significant differences between
treated and un-treated groups.
doi:10.1371/journal.pone.0020954.g007
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stage that CTCF releases Pax6 from a negative transcription
control. The rest of the study contributed to investigate
mechanisms underlying the decreased interaction of CTCF with
its binding motif in Pax6 promoter in radial glial cells.
Regulation of CTCF binding with its target DNA sequences is
often through a methylation-sensitive mechanism. For example,
CTCF epigenetically controls IGF-2/H19 expression by binding to
a differentially methylated domain (DMD) determined as
imprinted control region (ICR) [26]. Three potential methylation
sites (CG-rich islands) are tested inside the region where CTCF
binding motifs are found. Site 1 was a low methylated site with
approximately 15% methylation, suggesting that site 1 is unlikely
to play a major role in methylation-modifed CTCF occupancy in
control ES cells. However, methylation levels in sites 2 and 3 are
rather higher in control cells and changed from 55% to 32% and
80% after 5-azadCyd-induced demethylation and Dnmt3a
transfection-enhanced methylation, respectively (Fig. 4). The
results not only demonstrate that there are 3 methylation sites
inside of CTCF binding region, but also verify that 5-azadCyd
treatment and Dnmt3a transfection can efficiently change
methylation status of CTCF occupancy to interact with its binding
motifs. Therefore, these results are helpful for us to understand the
effect of DNA methylation on CTCF binding capability and
control of Pax6 expression. Methylation in all of the three sites has
been quantitatively evaluated during ES cell differentiation. On
the 8
th day of EB formation, hypermethylation occurred in sites 2
and 3 is remarkable, indicating these sites may play major roles in
regulating CTCF occupancy and protein-DNA interaction with
Pax6 promoter. As reported in RA-induced ES cell differentiation
to neuron progenitor cells, there are predominant gains of DNA
methylation in promoters of several hundred genes. However,
there are a little changes of globle DNA methylation between
neuronal progenitors and terminal neurons [35]. This indicates
that promoter hypermethylation is less dynamic during a transition
to the terminal differentiation. We believed that there might be
different mechanism for down-regulating Pax6 expression during
terminal differentiation, such as polycomb-mediated repression.
Polycomb targets are very dynamic during linage commitment
and terminal differentiation [36,37].
More evidence shows that DNA hypermethylation occurring
within this region is parallel to decrease in CTCF occupancy and
to increase in Pax6 expression, suggesting that methylation of Pax6
gene plays a functional role in regulating Pax6 transcription that
associates with ES cell differentiation. To establish the connection
between releases of CTCF from its binding sites and hypermethy-
lation in the same region, it requires more evidence to show
whether mthylation/de-methylation regulates CTCF binding
capability. To address this question, we performed EMSA and
ChIP-based PCR to demonstrate the role that DNA methylation
plays in the region of Pax6 promoter to modulate the interaction
between CTCF and its binding motifs (Fig. 6). It believes in general
that methylation of CpG islands is a dynamic epigenetic marker
that undergoes extensive changes during ES cells differentiation,
which contributes to turn-on and turn-off of particular genes that
are closely related to ES cell pluripotency and self-renewal [38,39].
Thus, DNA methylation has become a target for developing
pharmacological agents to manipulate directional differentiation of
ES cells [40]. In the present study, hypermethylation in CTCF
binding motifs in the Pax6 promoter region occurring during ES
cell differentiation functionally regulates Pax6 activity associated
with altering CTCF binding capacity. In summary, the present
work provides a novel mechanism underlying the enhanced Pax6
expression during induction of neural progenitor cells from ES
cells. The methylation-sensitive regulation of Pax6 during neural
differentiation provides theoretical evidences for future develop-
ment of techniques to better control neural progenitor cell
generation from ES cells.
Materials and Methods
ES cell culture and treatments
Mouse J1 ES cells (purchased from ATCC) were cultured in
Knockout
TM D-MEM supplemented with 10% Knockout
TM
serum, 2 mM L-glutamine, 100 mM non-essential amino acid,
100 U/ml penicillin/100 mg/ml streptomycin and 1,000 U/ml
ESGROH in 0.1% gelatin coated dishes in a humidified incubator
at 37uC with 5% CO2. All reagents for cell culture except for
ESGROH (Chemicon International Inc, CA) were purchased from
Invitrogen
TM Life Technologies, (Grand Island, NY). For ES
differentiation experiments, ES cells were grown in non-adherent
dishes in suspension to form embryoid bodies (EB). On the forth
day of the EB formation, retinoic acid (5 mM) was added for
additional 4-day period. EB cells were dissociated after the 8
th day,
and cultured in poly-D-lysine/laminin-coated dished for 2 h in a
complete DMEM medium supplemented with N2 supplement and
human basic fibroblast growth factor (10 ng/ml). (Invitrogen, CA).
Neuronal precursor cells were induced by further culturing EB
cells in the neuronal precursors medium (Invitrogen, CA). The
stock solution of 5-Aza-29-deoxycytidine (5-AzadCyd, Sigma, St.
Louis, MO) was made at a concentration of 1 mM. The final
concentration of 5-AzadCyd used in treating ES cells was at 1 mM.
Chromatin-immunoprecipitation (ChIP) and PCR
ES and EB cells were cross-linked in 1% formaldehyde for
10 min before the reaction was quenched by glycine at a final
concentration of 125 mM for 5 min at room temperature. Cells
were then homogenized in 1 ml cell lysis buffer to release nuclei.
Isolated nuclei were re-suspended in 1 ml nuclear lysis buffer and
genomic DNAs were broken down into 1,2 kb fragments by
sonication. Chromatin samples were immuno-precipitated by
using CTCF-specific antibody (Millipore, Billerica, MA). The
antibody-protein-DNA complexes were pulled down by protein
A/G agarose pre-absorbed with salmon sperm DNA. Samples
were then treated with proteinase K at 55uC overnight. Purified
ChIP-DNA samples were analyzed by PCR using a pair of primers
targeted to CTCF binding sites in the Pax6 P0 promoter region
(sense: 59- TGTCGGGGGAGGAGCAAGAACC9 and antisense:
59- CCTGGAGGGGCGGGAGACT-39).
Gene transfections and RNA interference
The plasmid pCMV-SPORT6 containing the cDNA fragment
encoding full-length mouse cytosine-5-methyltransferase 3a
(Dnmt3a) was purchased from ATCCH (MGC-5662). The
pcDNA4 plasmid containing the cDNA fragment encoding full-
length mouse CTCF was constructed in our lab previously [27].
Plasmids (20 mg per sample) were transfected into ES cells (1610
6
suspended in 600 ml of PBS solution) through electroporation at a
setting of 250 V, 500 mF, and 75 V for 10 ms. Transfected cells
were placed in full-growth medium and transferred to two 0.1%
gelatin coated 60 mm culture dishes. Vectors without inserts were
also transfected into ES cells for control experiments. For RNA
interference experiments, specific primers that were complemen-
tary to CTCF mRNA (21 nucleotides plus other 8 nucleotides
complementary to T7 promoter) were designed in our lab [27].
Briefly, a pair of primers was used with a sense strand sequence of
‘‘aaggaaugucuucuuuacacc’’, and an antisense strand sequence of
‘‘aagguguaaagaagacauucc’’. In addition, a nonsilencing control
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and antisense: ‘‘aagcgaggaaucuaccgaaug’’) was also synthesized
and applied by using the same method. Sequence homologies of
siRNA primers were examined by using a NIH Blast program.
SiRNA was synthesized by in vitro transcription using a SilencerH
siRNA Construction Kit (Ambion, Inc., TX). Double-strand RNA
was synthesized by in vitro transcription using T7 RNA polymerase
followed by RNase digestions to obtain siRNA. SiRNAs that were
pre-mixed with Lipofectamine were used to transfect ES cells.
None-specific siRNAs were synthesized using the same kit and
transfected into ES cells for control experiments.
Western analysis
EScellswereharvestedbycentrifugationat2,000 gfor5 min.Cell
pellets were resuspended in lysis buffer containing (in mM): 20 Tris-
HCl-pH 7.5, 137 NaCl, 1.5 MgCl2, 2 EDTA, 10 sodium
pyrophosphate, 25 b-glycerophosphate, 10% glycerol, 1% Triton
X-100, 0.1% aprotinin, 0.1% leupeptin, 1 sodium orthovanadate, 1
phenylmethylsulfonyl fluoride. Equal amounts of denatured lysates
(15 mg) were fractionated by SDS-PAGE and fractionated proteins in
SDS-PAGE were electro-transferred onto a PVDF membrane. The
membranes were incubated with primary antibodies in Tris-buffered
saline containing 0.1% Tween 20 (TBST) containing 5% nonfat milk
o v e r n i g h ta t4 uC. All protein extracts were displayed in Coomassic
blue-stained gels to ensure the equal amount of proteins being loaded.
Antibodies against CTCF (sc-5916) and Pax6 (sc-11357) were
purchased from Santa Cruz Biotechnology. Antibody against
Dnmt3a was purchased from Calbiochem (Cat. 317282). Mouse
monoclonal antibody against b-actin (Sigma, St. Louis, MO) was
diluted at a ratio of 1:10,000. Specific signals were detected by using
Western Blotting Luminol reagents (Santa Cruz Biotechnology, CA).
Electrophoretic mobility shift assay (EMSA)
Two sets of double-stranded oligonucleotides (80 bp) with the
specific sequence of Pax6 promoter region contained all CTCF
binding sites. Three of the binding sites were modified with/without
replacements of 5-methylated cytosines (Operon Biotechnologies,
Huntsville, AL). The probes were labeled with c-
32P-deoxy-ATP
(,3,000 mCi/mmol) using a T4 polynucleotide kinase labeling kit
(Promega, WI) and purified with QIAquick nucleotide removal kit
(Qiagen, CA). Nuclear protein extracts (10 mg) were incubated in the
binding buffer containing 10 mM Tris-HCl (pH 7.5), 0.05 mg/ml
poly (dI-dC), 0.5 mM EDTA, 50 mM NaCl, 1 mM MgCl2,4 %
glycerol, and 0.5 mM DTT on ice for 15 min. Each binding reaction
(20 ml) was initiated by adding 68.8 fmol probes and incubated on ice
for 30 min. Gels were vacuum-dried and exposed to X-ray film for
autoradiography. Competition experiments were performed by pre-
incubating nuclear protein extracts with 1 pM of unlabeled probe on
ice for 30 min and by adding different isotope-labeled probes. For
super-shift assays, DNA-protein complexes were incubated for an
additional 30 min using antibodies specific to CTCF and to negative
control proteins.
DNA preparation and bisulfite modifications
Cells were digested in lysis buffer (100 mM Tris-HCl [pH 8.5],
5 mM EDTA, 0.2% sodium dodecyl sulfate (SDS), 200 mM
NaCl, 100 mg of proteinase K/ml) at 55uC followed by phenol-
chloroform extraction. Total genomic DNAs were obtained by
ethanol precipitated and cleaved by EcoR I digestion. The DNA
fragments were modified by a bisulfite treatment following a
method described previously [41,42]. In brief, denatured DNA
was mixed with freshly prepared 30 ml of 10 mM hydryquinone
(Sigma, MO) and 520 ml of 3 M Sodium bisulfite (Sigma, MO) at
pH 5.0. Samples were immerged in the mineral oil and incubated
at 55uC for 6 h. Modified DNA was purified using the Wizard
DNA Purification Resin kit (Promega, WI), and eluted into 50 ml
of dd-H2O. Modification was completed by NaOH treatment for
10 min at 37uC and by ethanol precipitation. DNA was re-
suspended in 20 ml of dd-H2O and used immediately or stored at
220uC.
PCR amplification and DNA sequencing
Bisulfate-treated DNA (2 ml) was used as a template in strand-
specific PCR amplification for the region of interest. Primer pairs
were purchased from Operon Biotechnologies (Huntsville, AL).
The PCR fragments were amplified under standard conditions
with a total 35 cycles at different annealing temperatures followed
by a final extension at 72uC for 10 min. Normal genomic DNA
without demethylation treatment was used as a control. PCR
product was purified and confirmed by DNA sequencing.
Quantitative methylation analysis with Ms-SNuPE
Ms-SNuPE reactions were performed following the method
described by Gonzalgo, et al. [43]. Briefly, purified PCR product
(10 ng) was used in each reaction containing: 16 PCR buffer,
1 mM of each Ms-SNuPE primer, 1 mCi of
32P-labeled dCTP or
dTTP and 1 U of Taq polymerase. Specific primers for Ms-
SNuPE were: (site 1) 59-TTTTTTTTTTTATTGTTTTTATT-
39, (site 2) 59-TTTTATTT(C)GGTTAAGGAG TG-39, and (site
3) 59-TTTGGTTAA GGAGTGC(T)AGG. All samples were
treated at 95uC for 1 min, 50–54uC for 2 min, 72uC for 1 min.
Reaction products were loaded onto 15% denaturing polyacryl-
amide gels with 7 M urea. Results were visualized by exposure of
X-ray films.
Statistical Analysis
For Western and Chip analysis, signals in the films and agarose
gels were scanned digitally and optical densities (OD) were
quantified by using the Image Calculator software. The relative
OD in Western analysis was calculated by normalizing the signals
from target proteins against intensities of loading controls. In Chip
assays, the relative density was calculated by normalizing PCR
signals from immunopricipitated target chromatins against signals
from the whole cell chromatin DNA. Data were plotted as
Mean6SE. Significant differences between the control and treated
groups were determined by One-way ANOVA and Student’s t test
at P,0.05.
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